EXKIVITY FDA approval date

The FDA approved EXKIVITY on 15 Sep 2021.

FDA approval date
15 Sep 2021

Drug identity has not yet been verified against registry records

Also recorded as MOBOCERTINIB SUCCINATE

Included trials

No linked trials for this drug yet. Browse all trials

PDUFA dates and FDA decisions

Date as reportedDrug / companyEventConditionEvidence
2021-09-15DayEXKIVITYFDA original application approvalFDA approval decisionNot specifiedOpen original source
Read source excerpt

{"application_number": "NDA215310", "applicant_as_listed_by_fda": "TAKEDA PHARMS USA", "brand_names": ["EXKIVITY"], "active_ingredients": ["MOBOCERTINIB SUCCINATE"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20210915", "matched_on": "drug record created from this FDA brand name"}

First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026